Probability of resistance and means of sensitive and resistant cells at the end of treatment with monotherapy.

<p>Means of the sensitive cells (), resistant cells (), and total tumor size (), as well as the probability of resistance (), are calculated for a tumor with an initial population of 1.6 ⋅ 10⁶ sensitive cells at the end of nine weeks of treatment. The dosing schedules depicted here include both types of monotherapies (erlotinib alone and evofosfamide alone) from all three optimization classes.